When was Vanda Pharmaceuticals founded?

Vanda Pharmaceuticals was founded in 2003 and raised its 1st funding round 1 year after it was founded.

Where is Vanda Pharmaceuticals located?

Vanda Pharmaceuticals is headquartered in Washington, DC, United States. It is registered at Washington, District Of Columbia.

How many employees does Vanda Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Vanda Pharmaceuticals is 659.

Is Vanda Pharmaceuticals a funded company?

Vanda Pharmaceuticals is a funded company, having raised a total of $33.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Oct 2004.

When was the latest funding round of Vanda Pharmaceuticals?

Vanda Pharmaceuticals' latest funding was a $***** Series B round on Dec 28, 2005, with participation from 0 investor.

Where does Vanda Pharmaceuticals rank among its competitors?

Vanda Pharmaceuticals ranks 3rd amongst 96 active competitors, of which 21 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was HMNC Brain Health, which secured $50M in Jun, 2026.

Who are the top competitors of Vanda Pharmaceuticals?

Vanda Pharmaceuticals' top competitors include Alto Neuroscience, Enveda and Beckley Psytech. Among them, HMNC Brain Health secured the most recent funding round in June, 2026.

Vanda Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of pharmaceutical products for treating CNS disorders. The company focused on the development and commercialization of products for the treatment of central nervous system disorders. It has developed products like fanapt and hetlioz for treating jet lag, smith-magenis syndrome, and others.

Website: vandapharma.com
Social
Registered Address: Washington, District Of Columbia

Key Metrics

Founded Year

2003

Location

Washington, DC, United States

Stage

Public

Total Funding

$33.5M in 2 rounds

Latest Funding Round

Series B, Dec 28, 2005, $*****

Investors

Domain Associates & 5 more

Ranked

3^rd among 96 active competitors

Employee Count

659 as on Sep 30, 2026

Similar Companies

Alto Neuroscience & 124 more

Exit Details

Public

View Vanda Pharmaceuticals' full profile

Vanda Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vanda Pharmaceuticals Inc. CIN: 30491827 , United States, Active	Dec 26, 999	-	358 (As on Dec 31, 2024)	-

Vanda Pharmaceuticals got listed on Apr 12, 2006.

Click here to take a look at Vanda Pharmaceuticals's IPO in detail

Vanda Pharmaceuticals has raised a total funding of $33.5M over 2 rounds. Its first funding round was on Oct 2004. Vanda Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of Vanda Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 28, 2005	3887439	Series B	2817516	3332722	1650454	8506164
Oct 2004	7800688	Series B	3645037	2493551	8631713	Domain Associates & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Vanda Pharmaceuticals's funding rounds and investors

Vanda Pharmaceuticals' employee count trend

Vanda Pharmaceuticals has 659 employees as of Sep 26. Here is Vanda Pharmaceuticals's employee count trend over the years:

Employee count trend for Vanda Pharmaceuticals

Uncover Vanda Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vanda Pharmaceuticals include Alto Neuroscience, Enveda and Beckley Psytech. Here is the list of Top 10 competitors of Vanda Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alpha Wave Global & 36 others	68/100
2nd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
3rd	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	Domain Associates, MedImmune Ventures & 4 others	59/100
4th	Beckley Psytech 2019, Oxford (United Kingdom), Series B	Developer of rapid-acting psychedelic medicines for mental health disorders	$153M	ATAI, Bain Capital & 28 others	62/100
5th	Seaport Therapeutics 2020, Boston (United States), Public	Developer of therapeutics to treat neuropsychiatric disorders	$325M	T. Rowe Price, Foresite Capital & 7 others	60/100
6th	Supernus Pharmaceuticals 2005, Rockville (United States), Public	Innovating CNS treatments, improving lives through neurological and psychiatric solutions	-	Abingworth, Westwicke & 6 others	59/100
7th	HMNC Brain Health 2010, Munich (Germany), Series B	Developer of targeted therapies for depression and other neuropsychiatric disorders	$41.5M	Maschmeyer Group, The Jahr Group & 10 others	55/100
8th	Reunion Neuroscience 2022, Toronto (Canada), Acquired	Developer of therapeutics for mental health conditions	$120M	MPM BioImpact, Novo Holdings & 7 others	54/100
9th	Neurovance 2011, Cambridge (United States), Acquired	Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder .	$53M	GBS, Novartis Venture Fund & 3 others	53/100
10th	Reviva Pharmaceuticals 2006, San Jose (United States), Public	Develops therapeutic drugs for treatment of central nervous system	$49.1M	Lynx Financial	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Vanda Pharmaceuticals's competitors? Click here to see the top ones

Vanda Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Vanda Pharmaceuticals's sector:

Free

Neurology - Sector Report

Edition: August, 2026 (73 Pages)

View all reports related to Vanda Pharmaceuticals

Media has covered Vanda Pharmaceuticals for a total of 26 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.